D.E. Shaw & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

D.E. Shaw & Co’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,600	Closed	-$2.73M	–	6089
2021 Q4	$2.73M	Sell	18,600 -10,800	-37%	-$1.68M	﹤0.01%	3064
2021 Q3	$5.2M	Sell	29,400 -20,000	-40%	-$3.22M	﹤0.01%	2073
2021 Q2	$7.98M	Hold	49,400	–	–	0.01%	1684
2021 Q1	$8.46M	Hold	49,400	–	–	0.01%	1474
2020 Q4	$10.8M	Buy	49,400 +30,700	+164%	+$6.64M	0.01%	1347
2020 Q3	$3.1M	Buy	18,700 +8,700	+87%	+$1.19M	﹤0.01%	2044
2020 Q2	$1.14M	Hold	10,000	–	–	﹤0.01%	2832
2020 Q1	$769K	Hold	10,000	–	–	﹤0.01%	2939
2019 Q4	$1.29M	Buy	+10,000	New	+$965K	﹤0.01%	2801
2019 Q3	–	Sell	-10,000	Closed	-$1.03M	–	4072
2019 Q2	$1.03M	Buy	+10,000	New	+$779K	﹤0.01%	2664

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's MRTX Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,693 shares — an estimated $452K sold.

D.E. Shaw & Co first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $39.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

D.E. Shaw & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
D.E. Shaw & Co sold 7,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $452K.
D.E. Shaw & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
D.E. Shaw & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $39.6M in Q3 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.